コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 d by 16 weeks of continuation treatment with sertraline hydrochloride.
2 A flexible (50-150 mg) daily dose of sertraline hydrochloride.
3 ydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride.
4 h the selective serotonin reuptake inhibitor sertraline hydrochloride.
5 ochloride per day, the 5-HT uptake inhibitor sertraline hydrochloride (50 mg/d), or the NE uptake inh
9 ormed to evaluate the safety and efficacy of sertraline hydrochloride and imipramine hydrochloride in
10 ated potentially hazardous concentrations of sertraline hydrochloride by deriving transcriptomic and
11 I, 2.40-2.89; 4 studies; 1262 patients), and sertraline hydrochloride (CYP2C19 IM vs NM RoM, 1.38; 95
12 ning months, 189 subjects were randomized to sertraline hydrochloride, desipramine hydrochloride, or
15 02 (95% confidence interval, 0.77-1.35); and sertraline hydrochloride, hazard ratio = 0.75 (95% confi
16 me Pathway describing the mechanism by which sertraline hydrochloride impacted R. subcapitata was pro
17 ents were randomized to acute treatment with sertraline hydrochloride in flexible daily dosages of 50
18 f the serotonin selective reuptake inhibitor sertraline hydrochloride in patients with panic disorder
21 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydroch
24 ns examined in the studies, methylphenidate, sertraline hydrochloride, ondansetron, amitriptyline, an